NCE-1 Intelligence & Market Opportunity

Kerendia

Finerenone

Cardiovascular agent

Oral Tablet

Approval Date

07-Sep-21

NCE-1 Date

07-Sep-25

NCE Date

07-Sep-26

Commercial snapshot

Market performance & projections

Revenue ($M)

947

CAGR (%)

0.1837

Projected sales, 2026–2032 ($M)

Analyst projection, $M per year

2026

973

2027

1284

2028

1610

2029

1859

2030

2022

2031

2225

2032

2422

Molecule profile

Details & specifications

Molecule

Finerenone

Innovator

BAYER HEALTHCARE PHARMACEUTICALS INC.

Dosage Form

Oral Tablet

Strength

20 mg, 40 mg, 10 mg

Therapeutic Category

Cardiovascular agent

Usage

To reduce the risk of kidney and heart complications in chronic kidney disease associated with type 2 diabetes

Good to know

Frequently asked questions

Why Spring Bio Solution

Intelligence you can file on

Verified regulatory data

Milestones tracked against primary FDA sources and refreshed continuously.

Analyst-built projections

Seven-year sales outlooks modeled by our pharma intelligence team.

First-to-file focus

Exclusivity windows framed around the decisions generics teams actually make.

Partnership on demand

From API sourcing to dossier support — one request starts the conversation.

Ready to act on this opportunity?

Talk to Spring Bio Solution about sourcing, licensing, and filing support for this molecule.